Literature DB >> 7097468

Ritodrine concentrations in maternal and fetal serum and amniotic fluid.

M van Lierde, K Thomas.   

Abstract

Ritodrine hydrochloride concentrations were measured by radioimmunoassay in maternal and fetal sera and amniotic fluid from eight, pregnant, volunteers. Each patient agreed to have 420 micrograms . kg-1 of ritodrine infused intra-venously over two hours prior to elective cesarian section. During infusion a blood sample was taken every 30 minutes from a maternal peripheral vein. Once anesthesia was established the infusion was discontinued. During surgery, samples were drawn from maternal peripheral vein, uterine vein, umbilical artery and vein, and amniotic fluid. All the children delivered were healthy and had a normal course during the neonatal period. Ritodrine concentrations in maternal and fetal compartments at the time of cesarian section were 54.2 +/- 11.8 ng/ml (mean +/- S.D.) in maternal peripheral vein, 37.5 +/- 10.3 ng/ml in uterine vein, 15.8 +/- 4.8 ng/ml in umbilical artery, 16.6 +/- 8.9 ng/ml in umbilical vein, and 15.2 +/- 8.7 ng/ml in amniotic fluid. There was a statistically significant difference (p less than 0.02, paired-t test) between the mean ritodrine concentrations in sera from the maternal peripheral vein and uterine vein. This difference probably reflects transplacental passage. The mean ratio of fetal vein and peripheral maternal vein serum ritodrine concentrations was 0.30 +/- 0.13 (mean +/- SD). The similarity between mean ritodrine concentrations in amniotic fluid, and sera from umbilical arterial and venous blood was striking. These results suggest that the fetus does not conjugate the drug.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7097468     DOI: 10.1515/jpme.1982.10.2.119

Source DB:  PubMed          Journal:  J Perinat Med        ISSN: 0300-5577            Impact factor:   1.901


  5 in total

Review 1.  A risk-benefit assessment of therapies for premature labour.

Authors:  K Higby; C R Suiter
Journal:  Drug Saf       Date:  1999-07       Impact factor: 5.606

Review 2.  Placental transfer of drugs administered to the mother.

Authors:  G M Pacifici; R Nottoli
Journal:  Clin Pharmacokinet       Date:  1995-03       Impact factor: 6.447

3.  Plasma protein binding of ritodrine at parturition and in nonpregnant women.

Authors:  A S Gross; K F Brown
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

Review 4.  Clinical pharmacokinetics of beta-agonists.

Authors:  D J Morgan
Journal:  Clin Pharmacokinet       Date:  1990-04       Impact factor: 6.447

5.  Incidence and risk factors of neonatal hypoglycemia after ritodrine therapy in premature labor: a retrospective cohort study.

Authors:  Shoko Shimokawa; Akiko Sakata; Yukio Suga; Kazuya Isoda; Shingo Itai; Katsuhiko Nagase; Tsutomu Shimada; Yoshimichi Sai
Journal:  J Pharm Health Care Sci       Date:  2019-04-16
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.